PROSPECTS AND EFFICIENCY OF USING DOMESTIC ANIMAL BLOOD PRODUCTS IN MICROBIOLOGY AND MEDICAL FIELDS (LITERATURE REVIEW)

Modern medicine and the biopharmaceutical industry have achieved significant progress in the effective use of animal blood and its components. However, in our country, the dynamic development of the region requires greater attention from governmental bodies and sectoral organizations. The use of blood products derived from domestic animals, such as sheep and horses, presents broad opportunities for the production of microbiological culture media, as well as the development of medicinal products and immunobiological agents. Animal blood is utilized in the preparation of blood and serum agars, which contributes to improving the quality of diagnostics in clinical diagnostic laboratories. International regulatory acts, including the guidelines of the World Health Organization (WHO) and UNESCO declarations, restrict the commercial use of human blood, thus reinforcing the relevance of transitioning to animal-based sources. In Kazakhstan, the absence of stable domestic production of animal blood for laboratory purposes has led to the use of expired or human blood, posing infection risks and reducing diagnostic accuracy. The article highlights successful domestic developments, including the production of agar media and antitoxic preparations from horse and sheep blood by companies such as “EcoPharm International” and “Daryn-2030.” This review aims to identify the prospects, challenges, and innovative solutions related to the use of animal blood products, and emphasizes the need for governmental support and regulatory oversight of this sector in the Republic of Kazakhstan.

1. Byars T. D., Divers T. J. Clinical use of blood transfusions. – 1981.

2. Durham A. E. Blood and plasma transfusion in the horse //Equine Veterinary Education. – 1996. – Т. 8. – №. 1. – С. 8-12.

3. Cotter S. M. Clinical transfusion medicine //Advances in Veterinary Medicine. – 1991. – Т. 36. – С. 187-223.

4. Vincent J. L. et al. Anemia and blood transfusion in critically ill patients //Jama. – 2002. – Т. 288. – №. 12. – С. 1499-1507.

5. Goodnough L. T., Shander A. Blood management //Archives of pathology & laboratory medicine. – 2007. – Т. 131. – №. 5. – С. 695-701.

6. American Association of Blood Banks. Committee on Standards. Standards for blood banks and transfusion services. – The Committee, 1984. – Т. 160. – №. 2410.

7. Goodnough L. T. Alternatives to allogeneic transfusion in patients with surgical anemia //Transfusion Therapy: Clinical Principles and Practice. – 2005. – С. 243-263.

8. Chan T. et al. Consenting to blood: what do patients remember? //Transfusion Medicine. – 2005. – Т. 15. – №. 6. – С. 461-466.

9. Morris D. D. Review of anemia in horses, part II: pathophysiologic mechanisms, specific diseases and treatment. – 1989.

10. Stormont C. J. Blood groups in animals //Journal of the American Veterinary Medical Association. – 1982. – Т. 181. – №. 10. – С. 1120-1124.

11. Wilde H. et al. Heterologous antisera and antivenins are essential biologicals: perspectives on a worldwide crisis //Annals of internal medicine. – 1996. – Т. 125. – №. 3. – С. 233-236.

12. Dart R. C., McNally J. Efficacy, safety, and use of snake antivenoms in the United States //Annals of emergency medicine. – 2001. – Т. 37. – №. 2. – С. 181-188.

13. Mountain A., Adair J. R. Engineering antibodies for therapy //Biotechnology and Genetic Engineering Reviews. – 1992. – Т. 10. – №. 1. – С. 1-142.

14. Lewis R. J., Garcia M. L. Therapeutic potential of venom peptides //Nature reviews drug discovery. – 2003. – Т. 2. – №. 10. – С. 790-802.

15. Galfrè G., Milstein C. [1] Preparation of monoclonal antibodies: Strategies and procedures. – 1981.

16. Harris W. J. Production of humanised monoclonal antibodies for in vivo imaging and therapy //Animal Cell Technology: Basic & Applied Aspects: Proceedings of the Sixth International Meeting of the Japanese Association for Animal Cell Technology, Nagoya, Japan, November 9–12, 1993. – Dordrecht : Springer Netherlands, 1995. – С. 53-61.

17. World Health Organization et al. World Health Organization (WHO) guiding principles on human cell, tissue and organ transplantation //World Health Organization: Geneva, Switzerland. – 2010.

18. Hendriks A. Council of Europe-Convention for the protection of human rights and dignity of the human being with regard to the application of biology and medicine: Convention on human rights and biomedicine //Eur. J. Health L. – 1997. – Т. 4. – С. 89.

19. Lamotte K. R. United Nations Educational, Scientific and Cultural Organization (UNESCO): Universal Declaration on Cultural Diversity //International Legal Materials. – 2002. – Т. 41. – №. 1. – С. 57-62.

20. Lenk C., Beier K. Is the commercialisation of human tissue and body material forbidden in the countries of the European Union? //Journal of medical ethics. – 2012. – Т. 38. – №. 6. – С. 342-346.

21. Russell F. M. et al. As a bacterial culture medium, citrated sheep blood agar is a practical alternative to citrated human blood agar in laboratories of developing countries //Journal of clinical microbiology. – 2006. – Т. 44. – №. 9. – С. 3346-3351.

22. Sterzik B., FEHRENBACH* F. J. Reaction components influencing CAMP factor induced lysis //Microbiology. – 1985. – Т. 131. – №. 4. – С. 817-820.